Interview with Nicholas J. Robert, MD, about Phase II Study Results

Listen to Nicholas J. Robert, MD, Operations Co-Chair, Breast Cancer Research Committee, US Oncology Research, Inc., discuss the findings of the Phase II study that showed BSI-201, a potent PARP-1 inhibitor, to be promising for treating triple-negative breast cancer when administered in combination with standard chemotherapy.